Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02XJJ
|
|||
| Drug Name |
LM11A-31
|
|||
| Indication | Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Phase 1/2 | [1], [2] | |
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Low-affinity nerve growth factor receptor (NGFR) | Target Info | Modulator | [3], [4], [5] |
| KEGG Pathway | Ras signaling pathway | |||
| Rap1 signaling pathway | ||||
| Cytokine-cytokine receptor interaction | ||||
| PI3K-Akt signaling pathway | ||||
| Neurotrophin signaling pathway | ||||
| Transcriptional misregulation in cancer | ||||
| Pathway Interaction Database | p75(NTR)-mediated signaling | |||
| Neurotrophic factor-mediated Trk receptor signaling | ||||
| Reactome | Axonal growth inhibition (RHOA activation) | |||
| NRAGE signals death through JNK | ||||
| p75NTR negatively regulates cell cycle via SC1 | ||||
| Regulated proteolysis of p75NTR | ||||
| NADE modulates death signalling | ||||
| NRIF signals cell death from the nucleus | ||||
| p75NTR recruits signalling complexes | ||||
| NF-kB is activated and signals survival | ||||
| Axonal growth stimulation | ||||
| WikiPathways | Spinal Cord Injury | |||
| BDNF signaling pathway | ||||
| Signalling by NGF | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Small molecule p75NTR ligand prevents cognitive deficits and neurite degeneration in an Alzheimer's mouse model.Neurobiol Aging.2013 Aug;34(8):2052-63. | |||
| REF 4 | A small molecule p75(NTR) ligand protects neurogenesis after traumatic brain injury.Stem Cells.2013 Nov;31(11):2561-74. | |||
| REF 5 | A small molecule p75NTR ligand, LM11A-31, reverses cholinergic neurite dystrophy in Alzheimer's disease mouse models with mid- to late-stage disease progression.PLoS One.2014 Aug 25;9(8):e102136. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.